2024
Real‐world outcomes of intensive induction approaches in core binding factor acute myeloid leukemia
Rojek A, McCormick B, Cwykiel J, Odetola O, Abaza Y, Nai N, Foucar C, Achar R, Shallis R, Bradshaw D, Standridge M, Kota V, Murthy S, Badar T, Patel A. Real‐world outcomes of intensive induction approaches in core binding factor acute myeloid leukemia. EJHaem 2024, 5: 728-737. PMID: 39157611, PMCID: PMC11327707, DOI: 10.1002/jha2.981.Peer-Reviewed Original ResearchPatients treated with ICEvent-free survivalTreated with ICCore binding factor acute myeloid leukemiaGemtuzumab ozogamicinIntensive chemotherapyCBF-AMLAcute myeloid leukemiaKIT inhibitorsOverall survivalEuropean LeukemiaNetMyeloid leukemiaThree-year overall survivalMedian follow-upInduction treatment regimensAntibody-drug conjugatesStatistically significant differenceImproved OSFavorable riskSurvival benefitTreatment regimensProspective studyFollow-upCompare outcomesAcademic centers
2020
Leukocytapheresis for patients with acute myeloid leukemia presenting with hyperleukocytosis and leukostasis: a contemporary appraisal of outcomes and benefits
Shallis RM, Stahl M, Bewersdorf JP, Hendrickson JE, Zeidan AM. Leukocytapheresis for patients with acute myeloid leukemia presenting with hyperleukocytosis and leukostasis: a contemporary appraisal of outcomes and benefits. Expert Review Of Hematology 2020, 13: 489-499. PMID: 32248712, DOI: 10.1080/17474086.2020.1751609.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsWhite blood cell countAcute myeloid leukemiaTumor lysis syndromeMyeloid leukemiaPeripheral white blood cell countEvidence-based clinical guidelinesTotal white blood cell countEnd-organ damageRelevant patient outcomesWide practice variationBlood cell countPeripheral myeloblastsLysis syndromeIntravascular coagulationSurvival benefitOrgan damageClinical guidelinesPatient outcomesPractice variationLeukocytapheresisHigh riskCytoreductive strategyCell countHyperleukocytosisCells/L